title: Long-term effect of latanoprost on central corneal thickness in normal-tension glaucoma: five-year follow-up results.
abstract: OBJECTIVE
  To evaluate the long-term effect of latanoprost on central corneal thickness (CCT) in patients with normal-tension glaucoma (NTG).
  
  
  METHODS
  This retrospective study included 41 eyes of 41 NTG patients and 40 eyes of 40 individuals with glaucoma suspect (controls). Newly diagnosed NTG patients with no previous glaucoma treatment were administered latanoprost 0.005% monotherapy once a day. CCTs were measured by ultrasound pachymetry before treatment and followed up annually for 5 years.
  
  
  RESULTS
  A significant reduction in mean CCT was observed in the NTG group [542.3±36.2 μm vs. 533.7±32.9 μm (n=41), P<0.001], but not in the control group [547.4±24.7 μm vs. 546.8±25.0 μm (n=40), P=0.59] at 5-year follow-up. In the NTG group, the CCT reduction mainly occurred during the first year of treatment (542.3±36.2 μm vs. 536.9±32.8 μm, P=0.001), and no significant correlation was found between CCT and intraocular pressure reductions (r=0.16, P=0.32).
  
  
  CONCLUSIONS
  Latanoprost significantly reduced CCT in NTG patients after 5 years of treatment. Serial observations of CCT might be helpful for the proper interpretation of glaucoma status in NTG patients.
authors.affiliation: Department of Ophthalmology, Konkuk University Medical Center, Konkuk University School of Medicine , Seoul, Republic of Korea.
authors.forename: Hyungwoo
authors.initials: H
authors.lastname: Lee
authors.forename: Byung Joo
authors.initials: BJ
authors.lastname: Cho
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003315:Cornea / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology; D063171:Corneal Pachymetry / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D057066:Low Tension Glaucoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy*; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage* / Q000009:adverse effects; D012189:Retrospective Studies; D014463:Ultrasonography
chemical_list: D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost